PubAg

Main content area

TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer

Author:
Dong, Liming, Ding, Honglin, Li, Yanpei, Xue, Dongwei, Li, Zhi, Liu, Yili, Zhang, Teng, Zhou, Jian, Wang, Ping
Source:
International journal of biological macromolecules 2019 v.121 pp. 200-206
ISSN:
0141-8130
Subject:
blood serum, cell lines, cell movement, cell proliferation, gain-of-function mutation, gene overexpression, loss-of-function mutation, lymph nodes, messenger RNA, metastasis, microarray technology, neoplasm cells, oncogenes, patients, prognosis, prostatic neoplasms, thyroid hormone receptors
Abstract:
Thyroid hormone receptor interactor 13 (TRIP13) has been reported to be overexpressed in serval types of human cancers, and regulate tumor cell proliferation, migration and invasion. However, the role of TRIP13 in prostate cancer was still unclear. In our study, the correlation between TRIP13 expression and clinical parameters including prognosis was evaluated in 160 prostate cancer patients. Moreover, the MTT assay, cell migration and invasion assays were performed to assess the effect of TRIP13 on prostate cancer cell biological behaviour. In our results, the expression status of TRIP13 was observed to be elevated in prostate cancer tissue samples through analyzing microarray (GSE55945). Furthermore, mRNA and protein TRIP13 expression were confirmed to be overexpressed in prostate cancer tissue samples and cell lines. High-expression of TRIP13 was correlated with present lymph node involvement, distant metastasis, high Gleason score, levels of serum PSA and poor prognosis in prostate cancer patients. The gain-of-function and loss-of-function studies suggested that TRIP13 functioned as oncogene to regulate prostate cancer cell proliferation, migration, invasion through controlling YWHAZ and epithelial-mesenchymal transition (EMT)-associated genes. In conclusion, TRIP13 is correlated with clinical progression and poor prognosis, and serves as oncogene in prostate cancer.
Agid:
6154537